During the past decade, Hematology Oncology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 6 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology Oncology Associates" #1 sponsor was "Puma Biotechnology, Inc." with 2 trials, followed by "Tragara Pharmaceuticals, Inc." with 2 trials sponsored, "Acrotech Biopharma Inc." with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology Oncology Associates" #1 collaborator was "National Cancer Institute (NCI)" with 2 trials as a collaborator, "SWOG Cancer Research Network" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Cancer and Leukemia Group B" with 1 trials as a collaborator and "Eastern Cooperative Oncology Group" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Hematology Oncology Associates" are "Breast Cancer" (6 trials), "Advanced Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials), "Cachexia" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Hematology Oncology Associates" in a lesser frequency.

Most popular intervention types in "Hematology Oncology Associates" are "Drug" (16 trials), "Biological" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "cyclophosphamide" (2 trials), "placebo" (2 trials), "ABI-007 (Abraxane)" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hematology Oncology Associates" are 11 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Hematology Oncology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Hematology Oncology Associates, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology Oncology Associates, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".